[ABC of the antivirals] Project Inform. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

[ABC of the antivirals] Project Inform. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

Sidahora. 1996 Aug/Sep;:19-32. Unique Identifier : AIDSLINE AIDS/97702580

Abstract: Scientists have tried to inhibit or slow down the HIV virus ever since the virus was identified as the cause of AIDS. Although the efforts have not produced a long-term solution, significant progress has been made. There is a correlation between the increase in HIV levels and the advanced state of the disease. Antiviral therapies are discussed, including when to start the treatment, what drugs to use, and how to find out if the treatment is working. Some of the drugs seem to stop the replication of the HIV virus; however, they do not eradicate the virus. AZT (zidovudine/Retrovir), ddI (didadosine/Videx), ddC (zalcitabine/Hivid), d4T (stavudine/Zerit) and 3TC (lamivudine/Epivir) are some of the most common drugs on the market today. Information on research, side effects, doses, interactions with other drugs, and where to get these drugs is provided. Protease inhibitors, another type of drug, include saquinavir, ritonavir and indinavir (Crixivan). Much research has been done with these drugs, however, they are very difficult to produce. The combination of AZT and 3TC have shown positive results, and the future of antiviral therapies seems to be heading toward combination therapy.

Keywords: Anti-HIV Agents/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Drug Therapy, Combination HIV/DRUG EFFECTS/PHYSIOLOGY HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Human Virus Replication/DRUG EFFECTS NEWSLETTER ARTICLE
970830
M9781171

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .